PMC:7696151 / 9757-10049 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"233","span":{"begin":46,"end":51},"obj":"Gene"},{"id":"309","span":{"begin":212,"end":217},"obj":"Species"},{"id":"312","span":{"begin":230,"end":233},"obj":"Chemical"}],"attributes":[{"id":"A233","pred":"tao:has_database_id","subj":"233","obj":"Gene:3700"},{"id":"A309","pred":"tao:has_database_id","subj":"309","obj":"Tax:11676"},{"id":"A312","pred":"tao:has_database_id","subj":"312","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ls. Consequently, there was a modification of gp120 immunogenic properties and a reduction of new virions infectivity [15,16].\nThe first randomized, double-blind, placebo-controlled clinical trial about the anti-HIV-1 activity of HCQ was published in 1995. In this study, 40 asymptomatic HIV-"}

{"project":"LitCovid-sentences","denotations":[{"id":"T82","span":{"begin":4,"end":126},"obj":"Sentence"},{"id":"T83","span":{"begin":127,"end":256},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ls. Consequently, there was a modification of gp120 immunogenic properties and a reduction of new virions infectivity [15,16].\nThe first randomized, double-blind, placebo-controlled clinical trial about the anti-HIV-1 activity of HCQ was published in 1995. In this study, 40 asymptomatic HIV-"}